Skip to content
GenoLensGenoLens

SACS

Chr 13q12.12

sacsin molecular chaperone

Aliases:
ARSACS, KIAA0730, DKFZp686B15167, DNAJC29, SPAX6
MANE:
ENST00000382292.9

Annotations refreshed 1 month ago.

Predicted protein structure

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

  • Adult onset hereditary spastic paraplegia

    BIALLELIC, autosomal or pseudoautosomal
  • Albinism or congenital nystagmus

    BIALLELIC, autosomal or pseudoautosomal
  • Ataxia and cerebellar anomalies - narrow panel

    BIALLELIC, autosomal or pseudoautosomal
  • Childhood onset hereditary spastic paraplegia

    BIALLELIC, autosomal or pseudoautosomal
  • DDG2P

    BIALLELIC, autosomal or pseudoautosomal
  • Hereditary ataxia

    BIALLELIC, autosomal or pseudoautosomal
  • Hereditary ataxia with onset in adulthood

    BIALLELIC, autosomal or pseudoautosomal
  • Hereditary neuropathy

    BIALLELIC, autosomal or pseudoautosomal

+10 more panels — install the extension to see the full list inline on any page.

Disease associations (Open Targets)

  • Autosomal recessive spastic ataxia of Charlevoix-Saguenay

    0.82
  • Charlevoix-Saguenay spastic ataxia

    0.76
  • autosomal recessive limb-girdle muscular dystrophy type 2C

    0.58
  • Spastic paraplegia

    0.57
  • hereditary spastic paraplegia

    0.55
  • hereditary disease

    0.54
  • autosomal recessive limb-girdle muscular dystrophy

    0.51
  • autosomal recessive spastic ataxia

    0.48
  • Abnormal central motor function

    0.44
  • hereditary ataxia

    0.36

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Sacsin

Co-chaperone which acts as a regulator of the Hsp70 chaperone machinery and may be involved in the processing of other ataxia-linked proteins

Data sources: HGNC (CC BY 4.0), AlphaFold (CC BY 4.0, Jumper et al. Nature 2021), Genomics England PanelApp (CC BY 4.0), ClinGen, Open Targets (CC0), UniProt.

Not for sole clinical decision-making. Always verify against primary sources.